Amsterdam, NL, March 6, 2017 - There has long been interest in whether monoamine oxidase type B (MAO-B) inhibitors slow progression of Parkinson's disease (PD) and improve long-term outcomes. They ...

Announcing a new publication for Acta Materia Medica journal. Monoamine oxidase (MAO) is a useful target in the treatment of neurodegenerative diseases and depressive disorders. Understanding the ...

Monoamine oxidase inhibitors (MAOIs) are medications for depression. They take time to work but can be helpful along with other therapies and lifestyle changes. However, they have more side effects ...

Announcing a new publication for Acta Materia Medica journal. Monoamine oxidase (MAO) is a useful target in the treatment of neurodegenerative diseases and depressive disorders. Understanding the ...

There has long been interest in whether monoamine oxidase type B (MAO-B) inhibitors slow progression of Parkinson's disease (PD) and improve long-term outcomes. They have shown neuroprotective effects ...

There has long been interest in whether monoamine oxidase type B (MAO-B) inhibitors slow progression of Parkinson's disease (PD) and improve long-term outcomes. Monoamine oxidase type B (MAO-B) ...

What Are Monoamine Oxidase Inhibitors? Monoamine oxidase inhibitors (MAOIs) are an extremely strong class of antidepressants that treat depression by preventing the breakdown of the brain chemicals ...

Inhibiting human monoamine oxidase (MAO)-B to increase the availability of monoamine neurotransmitters is a clinically approved strategy for treating Parkinson’s disease, yet available inhibitors lack ...

Monoamine oxidase inhibitors (MAOIs) have a long and prosperous history as medications for major depressive disorder (MDD). But this type of antidepressant has mostly seen its day. Though MAOIs are ...

Although nicotine is generally considered to be the main compound responsible for the addictive properties of tobacco, experimental data indicate that nicotine does not exhibit all the characteristics ...